JP2008504264A5 - - Google Patents

Download PDF

Info

Publication number
JP2008504264A5
JP2008504264A5 JP2007518152A JP2007518152A JP2008504264A5 JP 2008504264 A5 JP2008504264 A5 JP 2008504264A5 JP 2007518152 A JP2007518152 A JP 2007518152A JP 2007518152 A JP2007518152 A JP 2007518152A JP 2008504264 A5 JP2008504264 A5 JP 2008504264A5
Authority
JP
Japan
Prior art keywords
methyl
thio
bis
compound
methylcyclopropyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2007518152A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008504264A (ja
JP5362986B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2005/021642 external-priority patent/WO2006009940A1/en
Publication of JP2008504264A publication Critical patent/JP2008504264A/ja
Publication of JP2008504264A5 publication Critical patent/JP2008504264A5/ja
Application granted granted Critical
Publication of JP5362986B2 publication Critical patent/JP5362986B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2007518152A 2004-06-23 2005-06-20 癌治療のためのビス(チオ‐ヒドラジドアミド)塩 Expired - Fee Related JP5362986B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US58259604P 2004-06-23 2004-06-23
US60/582,596 2004-06-23
US68136805P 2005-05-16 2005-05-16
US60/681,368 2005-05-16
PCT/US2005/021642 WO2006009940A1 (en) 2004-06-23 2005-06-20 Bis(thio-hydrazide amide) salts for treatment of cancers

Publications (3)

Publication Number Publication Date
JP2008504264A JP2008504264A (ja) 2008-02-14
JP2008504264A5 true JP2008504264A5 (enExample) 2008-08-07
JP5362986B2 JP5362986B2 (ja) 2013-12-11

Family

ID=34993190

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007518152A Expired - Fee Related JP5362986B2 (ja) 2004-06-23 2005-06-20 癌治療のためのビス(チオ‐ヒドラジドアミド)塩

Country Status (21)

Country Link
US (5) US7385084B2 (enExample)
EP (2) EP1781604B1 (enExample)
JP (1) JP5362986B2 (enExample)
KR (1) KR101313027B1 (enExample)
CN (1) CN1993318B (enExample)
AU (1) AU2005265202B2 (enExample)
BR (1) BRPI0512526A (enExample)
CA (1) CA2570698C (enExample)
DK (1) DK1781604T3 (enExample)
ES (1) ES2430373T3 (enExample)
HR (1) HRP20131023T1 (enExample)
IL (1) IL179632A (enExample)
ME (1) ME01644B (enExample)
NO (1) NO20070378L (enExample)
NZ (1) NZ552159A (enExample)
PL (1) PL1781604T3 (enExample)
PT (1) PT1781604E (enExample)
RS (1) RS52999B (enExample)
RU (2) RU2406722C2 (enExample)
TW (1) TWI389684B (enExample)
WO (1) WO2006009940A1 (enExample)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI332943B (en) 2001-07-10 2010-11-11 Synta Pharmaceuticals Corp Taxol enhancer compounds
TWI252847B (en) * 2001-07-10 2006-04-11 Synta Pharmaceuticals Corp Synthesis of taxol enhancers
TWI297335B (en) * 2001-07-10 2008-06-01 Synta Pharmaceuticals Corp Taxol enhancer compounds
TWI330079B (en) * 2003-01-15 2010-09-11 Synta Pharmaceuticals Corp Treatment for cancers
ES2430373T3 (es) 2004-06-23 2013-11-20 Synta Pharmaceuticals Corp. Sales de bis(tio-hidrazida amida) para tratamiento de cánceres
AU2005306471B2 (en) 2004-11-19 2009-12-17 Synta Pharmaceuticals Corp. Bis(thio-hydrazide amides) for increasing Hsp70 expression
WO2006113572A1 (en) * 2005-04-15 2006-10-26 Synta Pharmaceuticals Corp. Methods of increasing natural killer cell activity for therapy
NZ562572A (en) 2005-04-15 2011-01-28 Synta Pharmaceuticals Corp Combination cancer therapy with BIS (thiohydrazide) amide compounds
NZ563124A (en) * 2005-05-16 2010-12-24 Synta Pharmaceuticals Corp Synthesis of bis(thio-hydrazide amide) salts
CA2618723C (en) * 2005-08-16 2014-05-27 Synta Pharmaceuticals Corp. Bis(thio-hydrazide amide) formulation
US20100310587A1 (en) * 2005-08-29 2010-12-09 Academia Sinica Immunomodulatory compositions
GB0607950D0 (en) * 2006-04-21 2006-05-31 Novartis Ag Organic compounds
WO2008024305A2 (en) * 2006-08-21 2008-02-28 Synta Pharmaceuticals Corp. Bis (thiohydrazide amides) for treating melanoma
EP2059236A2 (en) * 2006-08-21 2009-05-20 Synta Pharmaceuticals Corporation Combination with bis(thiohydrazide amides) for treating cancer
WO2008024303A2 (en) * 2006-08-21 2008-02-28 Synta Pharmaceuticals Corp. Compounds for treating proliferative disorders
US20080176828A1 (en) * 2006-08-21 2008-07-24 Martin Williams Treating melanoma with BIS(THIOHYDRAZIDE AMIDES)
JP2010501563A (ja) * 2006-08-21 2010-01-21 シンタ ファーマシューティカルズ コーポレーション 増殖性障害を治療するための化合物
JP2010502616A (ja) 2006-08-31 2010-01-28 シンタ ファーマシューティカルズ コーポレーション 癌を治療するためのビス(チオヒドラジドアミド)の組み合わせ
US9498528B2 (en) * 2006-09-13 2016-11-22 Genzyme Corporation Treatment of multiple sclerosis (MS)
TW200829543A (en) * 2006-09-15 2008-07-16 Synta Pharmaceuticals Corp Purification of bis(thiohydrazide amides)
US8618170B2 (en) * 2007-11-09 2013-12-31 Synta Pharmaceuticals Corp. Oral formulations of bis(thiohydrazide amides)
US8581004B2 (en) 2008-02-21 2013-11-12 Synta Pharmaceuticals Corp. Compounds for treating proliferative disorders
WO2009123704A2 (en) * 2008-03-31 2009-10-08 Synta Pharmaceuticals Corp. Process for preparing bis(thiohydrazide amides)
US8461199B2 (en) 2008-10-22 2013-06-11 Synta Pharmaceuticals Corp. Transition metal complexes of a bis[thio-hydrazide amide] compound
KR20110073613A (ko) * 2008-10-22 2011-06-29 신타 파마슈티칼스 코프. 비스(티오하이드라자이드 아마이드) 화합물의 전이금속착체
US8525776B2 (en) * 2008-10-27 2013-09-03 Lenovo (Singapore) Pte. Ltd Techniques for controlling operation of a device with a virtual touchscreen
CA2745065A1 (en) 2008-12-01 2010-06-10 Synta Pharmaceuticals Corp. Compounds for treating proliferative disorders
RU2400471C1 (ru) * 2009-04-30 2010-09-27 Учреждение Российской академии наук Институт органической химии им. Н.Д. Зелинского РАН (ИОХ РАН) N-замещенные производные тиогидразидов оксаминовых кислот, способ их получения и их использование
WO2011069159A2 (en) * 2009-12-04 2011-06-09 Synta Pharmaceuticals Corp. Bis[thiohydrazide amide] compounds for treating leukemia
WO2011133673A1 (en) 2010-04-20 2011-10-27 Synta Pharmaceuticals Corp. Use of bis [thiohydrazide amide] compounds such as elesclomol for treating cancers
EP2640372A1 (en) 2010-11-18 2013-09-25 Synta Pharmaceuticals Corp. Preselection of subjects for therapeutic treatment with elesclomol based on hypoxic status
EP2776021A1 (en) * 2011-11-10 2014-09-17 Synta Pharmaceuticals Corp. Administration of a bis(thiohydrazide amide) compound for treating cancers
US20130149392A1 (en) 2011-12-12 2013-06-13 Synta Pharmaceuticals Corp. Method of treating non-small cell lung cancer with bis-(thiohydrazide)amide compounds
WO2013103795A1 (en) 2012-01-05 2013-07-11 The Board Of Trustees Of The Leland Stanford Junior University Bis (thiohydrazide amide) compounds for treating cancers

Family Cites Families (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2097737A5 (en) 1970-07-14 1972-03-03 Berlin Chemie Veb Virustatic 4-substd 1-acylthiosemicarbazides -from carboxylic acid - hydrazide and isothiocyanates or from carboxylic acid chloride and 4-
DE2037257A1 (en) 1970-07-28 1972-02-03 Farbwerke Hoechst AG, vorm. Meister Lucius & Brüning, 6000 Frankfurt Poly-(5-amino-1,3,4-thiadiazol-2-yl) derivs prepn - intermediates for drug and polymer prodn
GB1272920A (en) 1971-03-15 1972-05-03 Berlin Chemie Veb New thiosemicarbazides
US4012360A (en) * 1973-12-03 1977-03-15 Ciba-Geigy Corporation Bis-salicyloyl-dicarboxylic acid dihydrazides as stabilizers for polyolefines
JPS5091056A (enExample) 1973-12-17 1975-07-21
US4822777A (en) 1987-02-27 1989-04-18 Liposome Technology, Inc. Amphotericin B/cholesterol sulfate composition
JP2767241B2 (ja) 1987-04-15 1998-06-18 ロ−ム アンド ハ−ス コンパニ− 殺虫性のn−(場合により置換された)−n′−置換−n,n′−ジ置換ヒドラジン
US6013836A (en) * 1992-02-28 2000-01-11 Rohm And Haas Company Insecticidal N'-substituted-N,N'-disubstitutedhydrazines
FR2697752B1 (fr) 1992-11-10 1995-04-14 Rhone Poulenc Rorer Sa Compositions antitumorales contenant des dérivés du taxane.
CH683965A5 (it) * 1993-02-19 1994-06-30 Limad Marketing Exp & Imp Composti della classe dei ftalidrazidici come sostanza attiva in agenti antinfiammatori ed antitossici.
US6753006B1 (en) 1993-02-22 2004-06-22 American Bioscience, Inc. Paclitaxel-containing formulations
US5439686A (en) 1993-02-22 1995-08-08 Vivorx Pharmaceuticals, Inc. Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor
US6096331A (en) 1993-02-22 2000-08-01 Vivorx Pharmaceuticals, Inc. Methods and compositions useful for administration of chemotherapeutic agents
WO1994018954A1 (en) 1993-02-22 1994-09-01 Vivorx Pharmaceuticals, Inc. Methods for in vivo delivery of biologics and compositions useful therefor
US6537579B1 (en) 1993-02-22 2003-03-25 American Bioscience, Inc. Compositions and methods for administration of pharmacologically active compounds
US5916596A (en) 1993-02-22 1999-06-29 Vivorx Pharmaceuticals, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
US6749868B1 (en) 1993-02-22 2004-06-15 American Bioscience, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
US5665382A (en) 1993-02-22 1997-09-09 Vivorx Pharmaceuticals, Inc. Methods for the preparation of pharmaceutically active agents for in vivo delivery
US5840746A (en) 1993-06-24 1998-11-24 Merck Frosst Canada, Inc. Use of inhibitors of cyclooxygenase in the treatment of neurodegenerative diseases
US5523325A (en) 1993-09-09 1996-06-04 Jacobson; Richard M. Amidrazones and their use as pesticides
JPH10501215A (ja) 1994-06-03 1998-02-03 ビーエーエスエフ アクチェンゲゼルシャフト カルバモイルカルボン酸ヒドラジド
WO1997011094A1 (en) * 1995-09-22 1997-03-27 Novo Nordisk A/S Novel variants of green fluorescent protein, gfp
US5739686A (en) 1996-04-30 1998-04-14 Naughton; Michael J. Electrically insulating cantilever magnetometer with mutually isolated and integrated thermometry, background elimination and null detection
US6235787B1 (en) * 1997-06-30 2001-05-22 Hoffmann-La Roche Inc. Hydrazine derivatives
GB9727524D0 (en) 1997-12-31 1998-02-25 Pharmacia & Upjohn Spa Synergistic antitumor composition containing a biologically active ureido compound
TW479053B (en) * 1998-10-19 2002-03-11 Agro Kanesho Co Ltd Hydrazineoxoacetamide derivatives and pesticides
ES2161594B1 (es) * 1998-12-17 2003-04-01 Servier Lab Nuevos derivados de la hidrazida, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
RU2191015C2 (ru) * 1999-11-05 2002-10-20 Общество с ограниченной ответственностью "Центр бифункциональных иммуномодуляторов" Динатриевая соль n-(6-метил-2,4-диоксо-1,2,3,4-тетрагидро-5h-пиримидинсульфон)-n'- изоникотиноилгидразида, проявляющая антимикробную и иммунотропную активность, и лекарственное средство на ее основе
US6322303B1 (en) * 2000-05-12 2001-11-27 David M. John Dunnage bag and method of making same
EP1164126A1 (de) * 2000-06-16 2001-12-19 Basf Aktiengesellschaft Salicylsäurehydrazid-Derivate, Verfahren und Zwischenprodukte zu ihrer Herstellung, sie enthaltende Mittel und ihre Verwendung zur Bekämpfung von Schadpilzen
US6365745B1 (en) * 2000-07-14 2002-04-02 Sumika Fine Chemicals Co., Ltd. Method for producing hydrazine derivative
CA2435829A1 (en) * 2001-01-25 2002-08-01 Guilford Pharmaceuticals Inc. Trisubstituted carbocyclic cyclophilin binding compounds and their use
CA2445967A1 (en) 2001-05-01 2002-11-07 Abbott Laboratories Compositions comprising lopinavir and methods for enhancing the bioavailability of pharmaceutical agents
US20040235813A1 (en) 2001-05-03 2004-11-25 Erich Wanker Compounds that inhibit hsp90 and stimulate hsp70 and hsp40, useful in the prevention or treatment of diseases associated with protein aggregation and amyloid formation
US6602907B1 (en) * 2001-06-08 2003-08-05 University Of Central Florida Treatment of breast cancer
TWI297335B (en) * 2001-07-10 2008-06-01 Synta Pharmaceuticals Corp Taxol enhancer compounds
TWI252847B (en) * 2001-07-10 2006-04-11 Synta Pharmaceuticals Corp Synthesis of taxol enhancers
TWI332943B (en) * 2001-07-10 2010-11-11 Synta Pharmaceuticals Corp Taxol enhancer compounds
US6924312B2 (en) * 2001-07-10 2005-08-02 Synta Pharmaceuticals Corp. Taxol enhancer compounds
AU2002361345B8 (en) 2001-11-28 2008-06-26 Ipsen Pharma S.A.S. 5-sulphanyl-4H-1,2,4-triazole derivatives and their use as medicine
TW200408407A (en) 2001-11-30 2004-06-01 Dana Farber Cancer Inst Inc Methods and compositions for modulating the immune system and uses thereof
AU2006228035B2 (en) 2003-01-15 2010-02-18 Synta Pharmaceuticals Corp. Bis (thio-hydrazide amide) compounds for treating multi-drug resistant cancer
TWI330079B (en) 2003-01-15 2010-09-11 Synta Pharmaceuticals Corp Treatment for cancers
US7705027B2 (en) 2003-02-11 2010-04-27 Vernalis (Cambridge) Limited Isoxazole compounds as inhibitors of heat shock proteins
KR100575251B1 (ko) 2003-03-03 2006-05-02 재단법인서울대학교산학협력재단 p38/JTV-1을 유효성분으로 하는 암 치료용 약학적조성물 및 암 치료용 약학적 조성물의 스크리닝 방법
KR100486693B1 (ko) * 2003-03-17 2005-05-03 삼성전자주식회사 금속 매립 방법
EP1493445A1 (en) 2003-07-04 2005-01-05 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Inhibition of stress-induced ligand-dependent EGFR activation
AR045595A1 (es) 2003-09-04 2005-11-02 Vertex Pharma Composiciones utiles como inhibidores de proteinas quinasas
KR100544347B1 (ko) 2003-12-11 2006-01-23 한국생명공학연구원 디아릴이소옥사졸계 화합물을 유효성분으로 함유하는 암 예방 및 치료용 약학적 조성물
EP1730124A4 (en) 2004-03-26 2009-04-01 Amphora Discovery Corp Certain compounds based on triazole, compositions and applications thereof
US7011923B2 (en) * 2004-04-07 2006-03-14 International Business Machines Corporation Negative photoresist and method of using thereof
ES2430373T3 (es) 2004-06-23 2013-11-20 Synta Pharmaceuticals Corp. Sales de bis(tio-hidrazida amida) para tratamiento de cánceres
US20060142393A1 (en) * 2004-09-16 2006-06-29 Sherman Matthew L Bis(thio-hydrazide amides) for treatment of hyperplasia
AU2005306471B2 (en) * 2004-11-19 2009-12-17 Synta Pharmaceuticals Corp. Bis(thio-hydrazide amides) for increasing Hsp70 expression
WO2006062732A2 (en) 2004-11-19 2006-06-15 Synta Pharmaceuticals Corp. Compounds acting at the centrosome
EP1919882A2 (en) 2005-02-17 2008-05-14 Synta Pharmaceuticals Corporation Isoxazole combretastatin derivatives for the treatment of proliferative disorders
WO2006113572A1 (en) 2005-04-15 2006-10-26 Synta Pharmaceuticals Corp. Methods of increasing natural killer cell activity for therapy
WO2006113493A2 (en) 2005-04-15 2006-10-26 Synta Pharmaceuticals Corp. Methods of determining cancer prognosis via natural killer cell activity
NZ562572A (en) 2005-04-15 2011-01-28 Synta Pharmaceuticals Corp Combination cancer therapy with BIS (thiohydrazide) amide compounds
NZ563124A (en) * 2005-05-16 2010-12-24 Synta Pharmaceuticals Corp Synthesis of bis(thio-hydrazide amide) salts
CA2618723C (en) 2005-08-16 2014-05-27 Synta Pharmaceuticals Corp. Bis(thio-hydrazide amide) formulation
CA2653222A1 (en) 2006-05-25 2007-12-06 Synta Pharmaceuticals Corp. Triazole compounds that modulate hsp90 activity
WO2008024305A2 (en) 2006-08-21 2008-02-28 Synta Pharmaceuticals Corp. Bis (thiohydrazide amides) for treating melanoma
EP2059236A2 (en) 2006-08-21 2009-05-20 Synta Pharmaceuticals Corporation Combination with bis(thiohydrazide amides) for treating cancer
US20080176828A1 (en) 2006-08-21 2008-07-24 Martin Williams Treating melanoma with BIS(THIOHYDRAZIDE AMIDES)
TW200817371A (en) 2006-08-21 2008-04-16 Synta Pharmaceuticals Corp Compounds for treating proliferative disorders
WO2008024298A1 (en) 2006-08-21 2008-02-28 Synta Pharmaceuticals Corp. Bis(thiohydrazide amides) for inhibiting angiogenesis
WO2008024303A2 (en) 2006-08-21 2008-02-28 Synta Pharmaceuticals Corp. Compounds for treating proliferative disorders
JP2010502616A (ja) 2006-08-31 2010-01-28 シンタ ファーマシューティカルズ コーポレーション 癌を治療するためのビス(チオヒドラジドアミド)の組み合わせ
EP2061430A2 (en) 2006-09-11 2009-05-27 Synta Pharmaceuticals Corporation Bis (thiohydrazide amides) formulation
WO2008033449A2 (en) 2006-09-14 2008-03-20 Synta Pharmaceuticals Corp. Compounds for the treatment of angiogenesis
TW200829543A (en) 2006-09-15 2008-07-16 Synta Pharmaceuticals Corp Purification of bis(thiohydrazide amides)
US20090093538A1 (en) 2007-01-03 2009-04-09 Synta Pharmaceuticals Corp Method for treating cancer
US8093425B2 (en) 2007-04-30 2012-01-10 Synta Pharmaceuticals Corp. Compounds for treating proliferative disorders
US8729111B2 (en) 2007-08-07 2014-05-20 Synta Pharmaceuticals Corp. Compounds for treating proliferative disorders
US8618170B2 (en) 2007-11-09 2013-12-31 Synta Pharmaceuticals Corp. Oral formulations of bis(thiohydrazide amides)
EP2225201A2 (en) 2007-11-28 2010-09-08 Synta Pharmaceuticals Corp. Polymorphs of n-malonyl-bis(n'-methyl-n'-thiobenzoylhydrazide)
JP5091056B2 (ja) 2008-08-28 2012-12-05 三甲株式会社 密閉容器の蓋部シール構造

Similar Documents

Publication Publication Date Title
JP2008504264A5 (enExample)
JP2008520697A5 (enExample)
TWI387579B (zh) 雙(硫代醯肼醯胺)鹽之合成
JP2008540658A5 (enExample)
RU2007101898A (ru) Соли бис (тиогидразидамида) для лечения рака
JP2019529490A5 (enExample)
RU2475478C2 (ru) Соединения для лечения пролиферативных расстройств
JP2010533715A5 (enExample)
CN115244053A (zh) 靶向蛋白降解化合物及其制备方法和应用
JP2019518766A5 (enExample)
JP2014520898A5 (enExample)
JP2011515483A5 (enExample)
JP2017511321A5 (enExample)
JP2011515482A5 (enExample)
JP2011509309A5 (enExample)
JP2013525458A5 (enExample)
JP2015523339A5 (enExample)
JP2006515858A5 (enExample)
JP2016519072A5 (enExample)
JP2009523841A5 (enExample)
AU2015355839A1 (en) Heterocyclic derivatives and use thereof
JP2012507567A5 (enExample)
JP2013504593A5 (enExample)
JP2012504608A5 (enExample)
JP2021508318A (ja) チューブリン阻害剤